Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as an injectable solution for intravenous and subcutaneous use. It stimulates neutrophil production in patients undergoing chemotherapy, bone marrow transplantation, or who have severe chronic neutropenia, and is indicated for several hematologic conditions where neutrophil recovery is essential.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with reliable cold‑chain logistics and regulatory support, ensuring product integrity from manufacture to delivery.

Neupogen (filgrastim) is used to stimulate neutrophil recovery in disorders affecting the myeloid lineage.

- Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk in patients receiving cytotoxic chemotherapy. - Aplastic anemia: promotes neutrophil production to improve blood counts in patients with bone‑marrow failure. - Bone marrow transplantation: supports engraftment by increasing neutrophil counts after transplant procedures. - Severe chronic neutropenia: raises neutrophil levels to decrease the frequency of severe infections in patients with persistent neutropenia.

Filgrastim may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bone pain: mild to moderate discomfort, often in the limbs or back. - Injection site reactions: redness, swelling or itching at the administration site. - Fever: transient elevations in body temperature. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening hemorrhage. - Acute respiratory distress syndrome (ARDS): severe lung inflammation. - Anaphylaxis or severe allergic reaction: rapid onset of hives, swelling, or breathing difficulty. - Leukocytosis with very high neutrophil counts: may increase risk of vascular occlusion.

Prior to initiating filgrastim therapy, several safety considerations should be reviewed. - Monitor blood counts: regular CBCs are needed to assess neutrophil response and avoid excessive leukocytosis. - Assess spleen size: evaluate for splenomegaly before treatment and monitor for abdominal pain during therapy. - Use caution in sickle cell disease: increased risk of vaso‑occlusive events has been reported. - Avoid in patients with known hypersensitivity to filgrastim or any excipients. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Filgrastim can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other myeloid growth factors: additive leukocytosis may increase risk of vascular complications. - Combination with cytotoxic chemotherapy agents that cause profound myelosuppression: may exacerbate bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: may blunt the neutrophil response to filgrastim. - Live vaccines: reduced vaccine efficacy; timing should be coordinated. - Certain antibiotics (e.g., β‑lactams): may alter filgrastim clearance or increase infusion reactions.